Skip to main content
Log in

Double-blind comparison of liquid antacid and placebo in the treatment of symptomatic reflux esophagitis

  • Original Articles
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Although antacids have been the mainstay of pharmacologic therapy for reflux esophagitis, their effectiveness has not been tested in a placebo-controlled double-blind trial. We report a double-blind comparison of liquid antacid vs placebo in the treatment of reflux esophagitis in 32 patients with chronic heartburn. Entry criteria included the presence of symptomatic gastroesophageal reflux confirmed by both an acid perfusion (Bernstein) test and by intraesophageal pH probe. Drug treatment consisted of 15 ml (80 mEq) doses of antacid (Maalox Therapeutic Concentration, William H. Rorer) or placebo taken 7 times daily, ie, 1 and 3 hr after meals and at bedtime. Both groups showed significant improvement (P<0.05) in both frequency and severity of heartburn. The time to reproduce heartburn with the timed Bernstein test was increased with both active drug and placebo therapy. The mean increase was 402% (41±20 sec to 169±66 sec) for the placebo group and 286% (42±16 to 120±57 sec) in the antacid group. Both the antacid and placebo groups showed improvement in the degree of esophagitis as assessed endoscopically. The current study asked: does regular antacid therapy have a favorable influence on the natural history of symptomatic reflux esophagitis, ie, does therapy heal or otherwise change esophagitis so that painful episodes are either less frequent, less severe, or both? We found that the natural history of symptomatic reflux esophagitis was to improve with either antacid or placebo. There was no significant difference in antacid or placebo on the (short-term) natural history of the disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Graham DY, Smith JL: Why are some apparently healthy people heavy antacid users? Gastroenterology 80:1161, 1981

    Google Scholar 

  2. Graham DY, Lanza F, Dorsch ER: Symptomatic reflux esophagitis: A double-blind controlled comparison of antacids and alginate Curr Ther Res 22:653–658, 1977

    Google Scholar 

  3. Behar J, Brand DL, Brown FC, Castell DO, Cohen S, Crossley RJ, Pope CE II, Winans CS: Cimetidine in the treatment of symptomatic gastroesophageal reflux. Gastroenterology 74:441–447, 1978

    Google Scholar 

  4. Meyer C, Berenzweig H, Kuljian B, Callachan C, McCallum RW: Controlled trial of antacid (AA) versus placebo (P) on relief of heartburn. Gastroenterology 76:1201, 1979 (abstract)

    Google Scholar 

  5. Bright-Asare P, Bahar J, Brand DL, Brown FC, Castell DO, Cohen S, Debas H, Diamant N, Hogan W, Johnson L, Kaye M, Knuff T, Morrison-Cleator IG, Pope CE, Winans C, Wong R: Effects of long term maintenance cimetidine (cim) therapy on gastroesophageal reflux disease (gerd). Gastroenterology 82:1025, 1982 (abstract)

    Google Scholar 

  6. McCallum RW, Ippoliti AF, Colley C: A controlled trial of metoclopramide in symptomatic gastroesophageal reflux. N Engl J Med 296:354–357, 1977

    Google Scholar 

  7. Farrell R, Roling GT, Castell DO: Cholinergic therapy of chronic heartburn: A controlled trial. Ann Intern Med 80:573–576, 1974

    Google Scholar 

  8. Thanik KD, Chey, WY, Shah, AN: Reflux esophagitis: Effect of oral bethanechol on symptoms and endoscopic findings. Ann Intern Med 93:805–808, 1980

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

The study was supported, in part, by a grant from William H. Rorer, Inc., Fort Washington, Pennsylvania.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Graham, D.Y., Patterson, D.J. Double-blind comparison of liquid antacid and placebo in the treatment of symptomatic reflux esophagitis. Digest Dis Sci 28, 559–563 (1983). https://doi.org/10.1007/BF01308159

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01308159

Keywords

Navigation